Study Tests Potential Herpes Vaccine
A study underway at the University of Alabama at Birmingham (UAB) aims to determine whether an experimental vaccine is safe and effective in preventing genital herpes in young women.
The study marks the final phase of testing for the candidate vaccine, called HERPEVAC, developed by GlaxoSmithKline (GSK).
"If proven effective it will be the first vaccine for a sexually transmitted disease," says Edward Hook, MD, professor of medicine.
Nationally, 40 sites are participating in the study, directed by the National Institute of Allergy and Infectious Diseases and GSK. In total, sites will enroll 7,500 women between the ages of 18 and 30 who do not have oral or genital herpes. UAB will enroll 500 volunteers.
Source: UAB
Top 7 Infection Control Today Articles of 2024: Insights and Innovations
December 30th 2024From advanced sterilization methods to combating antimicrobial resistance, Infection Control Today’s top articles of 2024 delivered actionable strategies for safer healthcare environments and improved patient outcomes.
Revolutionizing Infection Prevention: How Fewer Hand Hygiene Observations Can Boost Patient Safety
December 23rd 2024Discover how reducing hand hygiene observations from 200 to 50 per unit monthly can optimize infection preventionists' time, enhance safety culture, and improve patient outcomes.
Redefining Competency: A Comprehensive Framework for Infection Preventionists
December 19th 2024Explore APIC’s groundbreaking framework for defining and documenting infection preventionist competency. Christine Zirges, DNP, ACNS-BC, CIC, FAPIC, shares insights on advancing professional growth, improving patient safety, and navigating regulatory challenges.
Addressing Post-COVID Challenges: The Urgent Need for Enhanced Hospital Reporting Metrics
December 18th 2024Explore why CMS must expand COVID-19, influenza, and RSV reporting to include hospital-onset infections, health care worker cases, and ER trends, driving proactive prevention and patient safety.
